Population Council

Knowledge Commons

2-24-2020

Introduction of DMPA-SC self-injection in Ghana: A feasibility and
acceptability study using Sayana® Press
Dela Nai
Population Council

Patrick Aboagye
Kamil Fuseini
Elizabeth Tobey
Population Council

Aparna Jain
Population Council

See next page for additional authors

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh
Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society
Commons, Gender and Sexuality Commons, International Public Health Commons, and the Medicine and
Health Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Nai, Dela, Patrick Aboagye, Kamil Fuseini, Elizabeth Tobey, Aparna Jain, Nora Maresh, and Rebecca
Fertziger. 2020. "Introduction of DMPA-SC self-injection in Ghana: A feasibility and acceptability study
using Sayana® Press," Research report. Washington, DC: Population Council, The Evidence Project.

This Report is brought to you for free and open access by the Population Council.

Authors
Dela Nai, Patrick Aboagye, Kamil Fuseini, Elizabeth Tobey, Aparna Jain, Nora Maresh, and Rebecca
Fertziger

This report is available at Knowledge Commons: https://knowledgecommons.popcouncil.org/departments_sbsr-rh/
1088

A feasibility and acceptability study using
Sayana® Press
Dela Nai, Associate I, Population Council Ghana
Patrick Aboagye, Director of Family Health Division, Ghana Health Service
Kamil Fuseini, Programs Officer, Population Council Ghana
Elizabeth Tobey, Staff Associate, Population Council D.C.
Aparna Jain, Associate II, Population Council D.C.
Nora Maresh, Family Health Team Leader, USAID
Rebecca Fertziger, Deputy Director, Health Office, USAID
JANUARY 2020

RE SEA RC H REP ORT

Introduction of DMPA-SC
self-injection in Ghana:

The Evidence Project
Population Council
4301 Connecticut Avenue, NW, Suite 280
Washington, DC 20008 USA
tel +1 202 237 9400
evidenceproject.popcouncil.org
The Evidence Project is made possible by the generous support of the American
people through the United States Agency for International Development
(USAID) under the terms of cooperative agreement no. AID-OAA-A-13-00087.
The contents of this document are the sole responsibility of the Evidence Project and Population Council and
do not necessarily reflect the views of USAID or the United States Government.

The Evidence Project uses implementation science—the strategic generation,
translation, and use of evidence—to strengthen and scale up family planning and
reproductive health programs to reduce unintended pregnancies worldwide. The
Evidence Project is led by the Population Council.

Published in January 2020.
Suggested citation: Nai, Dela, Patrick Aboagye, Kamil Fuseini, Elizabeth Tobey, Aparna Jain, Nora Maresh,
and Rebecca Fertziger. 2020. “Introduction of DMPA-SC self-injection in Ghana: A feasibility and
acceptability study using Sayana® Press,” Research Report. Washington, DC: Population Council, The
Evidence Project.
© 2020. The Population Council, Inc.

Photo credit on cover page: A woman self-injects the contraceptive DMPA-SC (brand name Sayana® Press).
PATH/Gabe Bienczyck.

The study was conducted in collaboration with the Ghana Health Service at the national, regional, district, and
facility levels. We acknowledge members of the Technical Advisory Group (TAG) for their active participation
and guidance in the conceptualization, implementation, and monitoring of activities. We fondly remember the
late Antonio Quarshie-Awusah of PSI/Total Family Health Organization for his substantial contributions to the
TAG, particularly regarding the possible introduction of DMPA-SC into Ghana’s private sector.
We acknowledge the United States Agency for International Development (USAID), particularly Janean Davis
(Director of the Health Office, USAID Ghana) and Akua Kwateng-Addo (former Director of the Health Office,
USAID Ghana), as well as Mihira Karra, Maggwa Baker, and Erika Martin from USAID Washington, D.C., who
all provided valuable inputs in the study design, implementation, and/or the report.
We acknowledge our colleagues from the Population Council: Placide Tapsoba (former Country Director,
Ghana office), Laura Reichenbach (former Technical Director, Evidence Project), Augustine Ankomah (Country
Director, Ghana office), and Michelle Hindin (Reproductive Health Program Director and Director of the
Evidence Project) – for their guidance in the design and implementation of the study and review of the report.
We also acknowledge Demi Safo, a doctoral student who during her internship at Population Council,
contributed to the development of the questionnaires.
We acknowledge Pfizer, Inc. for the registration of Sayana® Press in Ghana, which approval by the Food and
Drugs Authority allowed for procurement. We acknowledge the United Nations Population Fund (UNFPA) for
procuring the doses needed for the study.
We acknowledge all stakeholders (government, private, and non-profit agencies) who attended the national
dissemination of study findings.
We acknowledge Jennifer Drake and other colleagues from PATH for the provider and client training resources
and for the guidance provided during the study design phase. We especially acknowledge Justine Komunyena
Tumusiime from PATH/Uganda for training Ghana’s first batch of Master Trainers.
The successful implementation of the study would not have been possible without the sustained engagement of
the Family Health Division, Regional Health Directors, Deputy Directors of Public Health, Regional Public
Health Nurses, and service providers in the Ashanti and Volta regions, as well as the Master Trainers and data
collectors.
Lastly, we expressly acknowledge all the study clients for their time and providing valuable information during
the study.

T H E EVI D EN CE PR OJ E CT | i

ACKNOWLEDGMENTS .......................................................................................................................................... I
LIST OF ACRONYMS ........................................................................................................................................... VI
EXECUTIVE SUMMARY ........................................................................................................................................ 1
BACKGROUND ..................................................................................................................................................... 5
RATIONALE ........................................................................................................................................................... 7
OBJECTIVES .......................................................................................................................................................... 8
METHODS ............................................................................................................................................................. 9
DESCRIPTION OF THE INTERVENTION ........................................................................................................... 14
RESULTS ............................................................................................................................................................. 19
DISCUSSION ....................................................................................................................................................... 41
REFERENCES ..................................................................................................................................................... 46
APPENDICES ...................................................................................................................................................... 48

i i | R ES EA R C H RE P OR T

Study sites, by location ............................................................................................................ 9
Expected client sample size, by region ................................................................................ 11
List of organizations involved in Technical Advisory Group ................................................ 17
Percent distribution of study participants by sociodemographic characteristics at first
injection ................................................................................................................................. 20
Continuation of DMPA-SC at 6 months by client background characteristics................... 29
Percent distribution of providers by sociodemographic characteristics ............................ 37

T H E EVI D EN CE PR OJ E CT | i i i

Similarities and differences between DMPA-IM and DMPA-SC ............................................. 6
A visual of the Uniject™ system ............................................................................................... 6
Most recently used family planning method among DMPA-SC clients .............................. 21
Clients’ selected mode of injection administration, by interview ....................................... 22
Clients’ mode of injection administration at 6 months, by age .......................................... 23
Clients’ mode of injection administration at 6 months, by marital status......................... 24
Clients’ mode of injection administration at 6 months, by education ............................... 25
Clients’ mode of injection administration at 6 months, by residence ............................... 26
Clients’ mode of injection administration at 6 months, by history of family planning
use .......................................................................................................................................... 27
Continuation and discontinuation of DMPA-SC and study withdrawal/loss to followup, by interview ...................................................................................................................... 28
Clients’ reported reasons for discontinuing DMPA-SC at 3 months or 6 months ............. 30
Aspects of acceptability among home self-injection clients at 3 months and 6
months ................................................................................................................................... 31
Reported benefits of home self-injection among clients who self-injected at home
at 3 months or 6 months ...................................................................................................... 32
Clients’ methods for storage and disposal of the DMPA-SC Uniject™ ............................... 33
Ease of storage and disposal of DMPA-SC .......................................................................... 34
Clients’ report of reinjection time at 6 months among those who self-injected at
home at 3 months and 6 months......................................................................................... 35
Changes in provider knowledge of DMPA-SC from pre-training to post-training ............... 38
Changes in provider knowledge of where DMPA-SC can be administered from pretraining to post-training ......................................................................................................... 39
Provider-reported preparedness to offer DMPA-SC services at post-training ................... 40

i v | R ES EA R C H RE P OR T

Study partners and expected roles ..................................................................................... 48
Client’s mode of injection administration at all interviews, by sociodemographic
characteristics ...................................................................................................................... 49
Visuals of DMPA-SC pack, disposable puncture-proof container, and used
UnijectTM devices .................................................................................................................. 50

T H E EVI D EN CE PR OJ E CT | v

Community-Based Health Planning and Services
Contraceptive prevalence rate
Census and Survey Processing System
Deputy Director for Public Health
Demographic and Health Survey
Depot Medroxyprogesterone Acetate
Depot Medroxyprogesterone Acetate intramuscular
Depot Medroxyprogesterone Acetate subcutaneous
Food and Drugs Authority
Family planning
Family Planning 2020
Family Health Division
Ghana Health Service
Intramuscular
International non-governmental organization
Junior secondary school/junior high school
Modern contraceptive prevalence rate
Non-governmental organization
Population Services International
Subcutaneous
Senior secondary school/Senior high school
Technical Advisory Group
Total fertility rate
United Nations Population Fund
United States Agency for International Development

v i | R ES EA R C H RE P OR T

As articulated in its FP2020 Commitment, Ghana aims to increase the modern contraceptive prevalence rate
(mCPR) among currently married or in-union women from 22 percent to 29 percent and among unmarried
adolescents from 32 percent to 35 percent by 2020, with a focus on improving access in peri-urban and rural
areas and at all service delivery levels, building the capacity of health providers, and improving the contraceptive
method mix. Injectables are the most commonly used family planning (FP) method among married women in
Ghana, with 8 percent of married women using the method, and a commonly used method among sexually
active unmarried women, with 7 to 8 percent using the method.
Most injectable users use depot medroxyprogesterone acetate (DMPA) administered intramuscularly (DMPAIM), though recently, a subcutaneous version of DMPA (DMPA-SC) has become more widely available. DMPASC—also known by its brand name Sayana® Press (a registered trademark of Pfizer Inc.)—has a shorter needle
and slightly lower dosage than DMPA-IM, but maintains a three-month injection frequency and has similar
safety features and potential side effects as DMPA-IM. DMPA-SC is suitable for community-based distribution
as well as self-injection by clients, due to it being small, light, and easy to use, and requiring minimal training.
The possible benefits of self-injection include increased access, privacy, and autonomy for its users.
The Evidence Project, led by the Population Council with support from the United States Agency for
International Development (USAID)/Ghana, collaborated with the Ghana Health Service (GHS) to conduct a
feasibility and acceptability study introducing DMPA-SC to health providers and FP clients in Ghana, results of
which would inform the scale-up of DMPA-SC, including self-injection, in the public and private sectors of the
country. The objectives of the study were to:
Assess the feasibility and acceptability of DMPA-SC service provision by FP providers and clients in
Ghana.
Assess the feasibility and acceptability of client self-injection by FP providers in Ghana.
Assess the feasibility and acceptability of self-injection by FP clients in Ghana.
The study was conducted in rural, peri-urban, and urban areas of the Ashanti and Volta regions of Ghana. All
FP-related providers at selected health facilities were eligible to participate in the study. Providers received a
three-day training on DMPA-SC counseling and subcutaneous administration, training clients to self-inject, and
observing and supervising clients’ use of DMPA-SC. Immediately before and after the training, providers
completed pre- and post-training assessments to gauge improvements in knowledge.
Clients who sought FP services and chose to use DMPA-SC after receiving counseling on the method were
eligible to participate in the study. After choosing DMPA-SC, clients were given the option to be trained on selfinjection and, if deemed competent by the provider, to self-inject under supervision of the provider and to take
two doses of DMPA-SC home for future self-injection. Clients who agreed to participate in the study were
interviewed at the facility after their first injection and over the phone or in person following their scheduled
second injection (3-month interview) and third injection (6-month interview).
A total of 568 clients who chose DMPA-SC agreed to participate in the study. Sixty percent were 18 to 29 years
old, 73 percent were married or in-union, and 71 percent had attained junior secondary level of schooling or
higher. Of 150 trained providers who participated in the study, 65 percent were community health nurses and
88 percent had at least one year of experience in their professional capacity. Key findings of the study included:
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Approximately four out of ten (41%) DMPA-SC clients in this study had never used any (modern or traditional)
method of FP.
•
•

Forty-eight percent of clients had recently used intramuscular injectables (DMPA-IM).
Seventy-one percent of clients who were new FP users continued to use DMPA-SC at 6 months,
compared with 64% of clients who had ever used any method of FP.

•

While just over one-third of DMPA-SC clients chose to self-inject their first time using DMPA-SC
(35%), nearly two-thirds (65%) chose to self-inject at 3 months and 6 months.
At 6 months, self-injection was more common among women 18 to 29 years (76%) compared to women
30 years and above (68%), never-married women (81%) compared to ever married/in-union women
(69%), first-time FP users (81%) compared to previous modern FP users (65%), and women living in
rural areas (87%) compared to urban residents (64%).

•

•
•

•
•
•
•

At 6 months, two out of three clients (67%) continued using DMPA-SC, a total of 9 months of
protection.
Continuation of DMPA-SC was more common among never-married (74%) compared to currently
married (65%) and previously married (59%) women. Women from the Volta region were more likely
to continue (75%) compared to women in the Ashanti region (58%).

44 percent of DMPA-SC clients chose to self-inject at home.
At 6 months, clients who took DMPA-SC doses home reported high satisfaction (98%) and comfort
(100%) with home self-injection.
Home self-injectors also reported benefits such as not having to travel to the facility (71%), not having
to wait at the facility (47%), privacy (42%), and not having to see a provider (37%).
Nearly all home self-injectors knew how to correctly store (96%) and dispose of (98%) the used
Uniject™ device, found it easy to store (94%) and dispose of (96%), and reinjected on time (85%)
(within an 11-to-17-week window after the previous injection).

At the end of the training, over 90 percent of providers correctly answered questions on five key characteristics
of DMPA-SC:
•
•
•
•

98 percent knew that Uniject™ is the injection device for DMPA-SC, an increase from 34 percent
before the training.
93 percent knew that DMPA-SC is administered subcutaneously, up from 29 percent before the training.
99 percent knew DMPA-SC is administered every 3 months, an increase from 52 percent before the
training.
100 percent knew that DMPA-SC must be stored at room temperature, compared to 55 percent before
the training.
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•

100 percent could name at least one location on the body where DMPA-SC can be injected, compared
to 61 percent before the training.

At the end of the training, almost all providers reported that they were very well prepared to offer DMPA-SC
services to clients:
•
•
•
•

94 percent of providers felt very well prepared to counsel clients on DMPA-SC.
93 percent felt very well prepared to administer DMPA-SC.
93 percent felt very well prepared to train clients to self-inject.
98 percent felt very well prepared to observe and supervise clients during self-injection.

The findings of this study suggest that providers can be trained to counsel their clients on DMPA-SC, administer
DMPA-SC, and train and supervise their willing clients to self-inject. Additionally, both providers and clients
found self-injection of DMPA-SC to be feasible and acceptable. The following recommendations aim to guide
the Ghana Health Service as it scales DMPA-SC up nationally:
:
•
•

•

Develop an implementation strategy for staggered rollout across the nation, in public and private health
facilities.
Utilize a cascade training approach similar to the study, whereby national and regional resources persons
are trained to become Master Trainers, who then train providers on-site. This will efficiently allow for
the number of providers who are trained to be maximized across the country.
Engage pharmacies and over-the-counter medical sellers in commodity resupply, enabling them to sell
DMPA-SC to women who have received self-injection training at the facility and amplifying the role of
the private sector in increasing uptake of DMPA-SC in Ghana.
:

•
•

Develop national guidelines and standards governing home self-injection of DMPA-SC, to be included
in the next edition of the National Reproductive Health Service Policy and Standards.
Develop national guidelines and standards for disposal and waste management of used devices for
facilities and home self-injection clients.
:

•

Raise awareness by integrating DMPA-SC in relevant health promotion and social marketing activities
in the community and at health facilities.
:

•
•
•

Enforce the use of the standard Adverse Reaction Reporting Form in public and private facilities as well
as pharmacies and over-the counter medical seller shops as part of pharmacovigilance.
Add DMPA-SC and its modalities as a method option on FP registries and daily logs, to enable public
and private facilities to contribute to national monitoring and reporting of DMPA-SC use.
Include global DMPA-SC indicators in monitoring and evaluation tools to enable comparisons of trends
with other countries.
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•

•

Develop an action plan for monitoring disposal and waste management for facilities and home selfinjection clients. While 95 percent of clients stored DMPA-SC correctly and 98 percent disposed of it
correctly, this study did not follow women for long enough to know if they would also return their
disposal container to the facility at the time of resupply.
Conduct regular assessments of client experiences with DMPA-SC, including reinjection, storage, and
disposal practices, as well as reasons for discontinuation of DMPA-SC, and a comparison of these
reasons to those for discontinuation of DMPA-IM. As self-injection is a new mode of administration
in Ghana, monitoring its use from the clients’ perspective will be critical in understanding successes and
challenges of home injection for learning across the region.
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Ghana’s Family Planning 2020 (FP2020) commitments include increasing the modern contraceptive prevalence
rate (mCPR) among currently married or in-union women to 29 percent and among unmarried adolescents to
35 percent by 2020, with a focus on improving access to voluntary family planning (FP) in peri-urban and rural
areas. Specifically, the Government of Ghana has made a commitment to increase the number of women using
modern contraception from 1.46 million as of 2015 to 1.93 million in 2020 via increased access and availability
of services at all service delivery levels, building capacity of health providers, improving the contraceptive
method mix, and increasing demand for FP services (FP2020 2017).
The most recent nationally representative data, the Ghana Demographic and Health Survey conducted in 2014
and the Ghana Maternal Health Survey conducted in 2017, indicate that the mCPR among married women is
between 22 percent (GSS et al. 2015) and 25 percent (GSS et al. 2018), and among sexually active unmarried
women is between 31 percent (GSS et al. 2017) and 32 percent (GSS et al. 2018), with a total fertility rate between
3.9 and 4.2 births per woman (GSS et al. 2018; GSS et al. 2015). A sizeable unmet need for FP remains, with
approximately 30 percent of married women and 42 percent of unmarried women in Ghana wanting either no
more children or to postpone childbearing for at least the next two years, but not using any method of
contraception (GSS et al. 2015).
In 1988, 0.3 percent of married women in Ghana reported using injectables; this proportion steadily increased
to 8 percent in 2014 (GSS et al. 2015), making injectables the most commonly used method among married
women. Among married modern contraceptive users, nearly one-third (32 percent) reported using an injectable,
and among unmarried modern contraceptive users, 22 percent use an injectable (GSS et al. 2017). With a failure
rate of less than one percent for perfect use and less than 4 percent for typical use (Trussell 2011; Polis et al.
2017), injectable contraceptives are highly effective, reversible, and convenient to use, and can ensure privacy
and secrecy (Adetunji 2011).
The most commonly used injectable contraceptive method by women around the world, including women in
Ghana, is the progestin-only depot medroxyprogesterone acetate (DMPA). DMPA can be administered either
as an intramuscular (IM) injection or as a subcutaneous (SC) injection. There are several similarities between
DMPA-SC and DMPA-IM, including three-month injection frequency, safety, and side effects (Figure 1, adapted
from PATH). Compared to DMPA-IM, DMPA-SC has a shorter needle and slightly lower dosage, and the
subcutaneous injection is administered using the all-in-one Uniject™ device (Figures 1 & 2). DMPA-SC is small,
light, and easy-to-use, and requires minimal training (PATH 2017a; PATH 2017b). DMPA-SC is often referred
to by its brand name of Sayana® Press1, a registered trademark of Pfizer, Inc.
The Uniject™ injection system has been described as especially suitable for community-based distribution and
for women to administer themselves through self-injection (PATH 2017a; PATH 2017b). As such, DMPA-SC
and the possibility of self-injection have become promising pathways for increasing access to a safe and effective
contraceptive option in low-resource settings (Keith et al. 2014). In addition, self-injection of DMPA-SC is a
method of self-care for women, and thus has the potential to increase the privacy and autonomy of users to
decide whether, when, and how many children to have (Murray et al. 2017). As of December 2018, DMPA-SC
In this report, DMPA-SC is used for general references to the injectable contraceptive method, while Sayana® Press is
used for specific references to the product used in the study and mentioned in data collection tools. At the time the study
was conducted, the product was widely referred to as Sayana® Press in Ghana and elsewhere. Of note is that providers
were trained on DMPA-SC, but for consistency with the product packaging, providers counseled and trained clients using
the name Sayana® Press.
1
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was available in about 20 FP2020 countries and has been approved by regulatory bodies in more than 40
countries around the world (PATH 2018). In Ghana, it is registered as Sayana® Press by Pfizer, Inc. and is
approved for use by the Food and Drug Authority.
Between 2012 and 2015, pilot studies on the feasibility and acceptability of DMPA-SC were undertaken in
Senegal and Uganda (Burke et al. 2014). Introductions of DMPA-SC began in Burkina Faso, Niger, Senegal, and
Uganda in 2014 through a variety of channels, including clinic and community-based health providers. In a span
of two years (2014-2016), providers administered more than 490,300 doses of DMPA-SC to women and reached
135,000 women who were first-time users of modern FP (PATH 2017a).
The pilot studies revealed a demand for self-injection. In Senegal and Uganda, close to 90 percent of clients
participating in studies demonstrated competency to self-inject three months after being trained by a provider,
and a large proportion of women in these studies expressed a desire to continue with self-injection (Cover et al.
2017a; Cover et al. 2017b). Subsequent studies on continuation conducted in Malawi, Senegal, Uganda, and the
United States all showed that over a 12-month period, women who self-injected DMPA-SC at home continued
using this injectable contraceptive method longer than their counterparts who received injections from clinic or
community-based providers (Burke et al. 2018; Cover et al. 2018; Cover et al. 2019; Kohn et al. 2018).
FIGURE 1. SIMI LARITIES AND D IFFERENCES BETWEEN D MPA-IM AND DMPA-SC
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In 2016, the Ghana Health Service (GHS) reached out to its partners, namely the United States Agency for
International Development (USAID), the United Nations Population Fund (UNFPA), Population Services
International (PSI), and Population Council, to undertake a feasibility and acceptability study regarding DMPASC self-injection, and, by extension, the introduction of the contraceptive method to the country (see Appendix
1 for study partner roles). At the time, acceptability studies had been conducted in Senegal and Uganda which
examined clients’ willingness to self-inject (Burke et al. 2014). Introduction of DMPA-SC through servicedelivery channels had commenced in Burkina Faso, Niger, Senegal, and Uganda.
Although three self-injection studies were ongoing in 2016 in Malawi, Senegal, and Uganda, results were not
available at the time the present study was conceived. There was, therefore, a palpable need to broaden the
evidence base on the feasibility and acceptability of DMPA-SC self-injection in Ghana and other sub-Saharan
countries. Moreover, Ghana aimed to contribute to the growing body of evidence by conducting a study in a
context where DMPA-SC and self-injection would be introduced simultaneously.
The current research study was funded by USAID/Ghana and led by the Population Council through the
Evidence Project. It was carried out in two regions and across eight public health facilities (four in the Ashanti
region and four in the Volta region), over an 8-month period.
This report details the study, including the objectives, intervention components, methodology, and results. It
also includes a discussion section that interprets the findings and a final section that highlights the utilization of
research findings to inform DMPA-SC scale-up.
FIGURE 2. A VI SUAL OF THE U N IJECT™ SYSTEM

Photo credit: PATH, copyright 2018.
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The aim of the study was to introduce DMPA-SC (using Sayana® Press) to health providers and FP clients in
Ghana. The study had three primary objectives:
Assess the feasibility and acceptability of DMPA-SC service provision by FP providers and clients in
Ghana.
Assess the feasibility and acceptability of client self-injection by FP providers in Ghana.
Assess the feasibility and acceptability of self-injection by FP clients in Ghana.
Results of the study have informed the scale-up of DMPA-SC, including self-injection, in the public and private
sectors of the country.
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The study was implemented with providers and clients of DMPA-SC in the Ashanti and Volta regions of Ghana.
The study included a quantitative self-assessment among providers trained in providing DMPA-SC and in
training clients to self-inject DMPA-SC. The assessment was implemented before the training and right after the
training concluded. For DMPA-SC clients, a prospective cohort study design was implemented. Clients who
selected DMPA-SC were interviewed at the facility after receiving their first injection and then again over the
phone after the scheduled second and third injections, which could have occurred at the facility or at home. In
some instances, clients’ second and third interviews were conducted in person when a phone interview was not
feasible either due to connectivity issues and/or client expressing a strong preference for an in-person interview.

The study was implemented in selected public health facilities in the Ashanti and Volta regions. The Ashanti
region is currently the most populous region of the country with approximately 5 million people. The total
fertility rate (TFR) in the Ashanti region is 4.4 births per woman and modern contraceptive prevalence rate
(mCPR) is 21 percent. The 2014 Demographic and Health Survey (DHS) showed that approximately 6 percent
of married women are using an injectable (GSS et al. 2015). The Volta region is home to approximately 3 million
people. The TFR is 3.6 births per woman and the mCPR of 30 percent is the highest in the nation (GSS et al.
2015). Furthermore, 14 percent of married women in the Volta region are using an injectable (GSS et al. 2015).
Both Ashanti and Volta regions are predominantly rural.
In each region, four facilities—two rural, one peri-urban, and one urban—were selected across four districts
(Table 1). The facilities were eligible for the study based on their rural/urban location, monthly caseload of
injectable users, and tracking of service statistics using rsLog.2 At the national level, the GHS Family Health
Division (FHD) informed the Regional Directors of the Ashanti and Volta Regional Health Directorates about
the study. The Regional Director and Deputy Director in Charge of Public Health (DDPH) then contacted
District Directors and Facility In-Charges of eligible facilities to inquire about their willingness to participate as
a study site.
TABLE 1. STUDY SITES, BY LO CATION
Ashanti Region
Maternal and Child Health Hospital
Abuakwa Health Centre
Piase CHPS
Fumso Health Centre

Volta Region
Council Hall Family Health Unit
Juapong Health Centre
Tsito Health Centre
Helekpe Health Centre

Location
Urban
Peri-Urban
Rural
Rural

rsLog is a health management information system tool developed by the GHS with technical assistance from Population
Council that allows for: monitoring of individual health worker performance by cadre; disaggregation of data by facility,
district, regional, and national levels; and generation of monthly electronic reports.
2
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Providers
Providers at selected facilities who had at least six months of experience providing FP services were eligible for
participation in the study. Eligible providers included community nurses, enrolled nurses, midwives, and others
providing FP services. Facility In-Charges were informed about the study and asked to provide a list of eligible
FP-related providers (i.e., reproductive and child health unit, antenatal unit, and outpatient unit) reporting to the
facility. These providers were informed about the study during a site visit in October 2017 and all FP-related
providers agreed to be recruited into the study in November 2017.
Clients
Clients eligible for the study included women aged 18-49 years who were seeking FP services at the selected
health facilities. Women who were planning on becoming pregnant in the next three months and those less than
6 weeks postpartum and breastfeeding were excluded from the study, as were those who were unable to provide
a phone number as a contact or unwilling to be reached by phone.
Trained providers counseled clients seeking FP services on a range of contraceptive methods. Providers were
trained to counsel clients on DMPA-SC and self-injection mode of administration and to provide an opportunity
to train clients on-site to self-inject. After a client who had chosen DMPA-SC received an injection (either
through self-administration or provider administration), providers informed them about the research study.
Clients who agreed to learn more about the study were introduced to a research team member stationed at the
facility. The research team member implemented the informed consent process. Written informed consent was
obtained from all clients. Clients who were not able to sign their name attested that the consent form had been
read and explained to them by a member of the research staff by marking the space with an “x.”
Clients were enrolled from December 2017 to January 2018 in the Ashanti and Volta regions until the desired
sample size was reached. The desired sample size was calculated based on an estimated 25 percent of DMPASC users choosing to self-inject after six months (or at the third injection).
The sample size was calculated based on the following formula:

Where, n = minimum sample size
Z= 1.96 (standard)
p = 0.25 (estimated proportion of DMPA-SC users who opt for self-injection at t0+6months)
d = 0.05 (5% absolute precision or margin of error)
The minimum sample size derived from this formula is 289. Given the longitudinal nature of the research, the
design effects, non-random sampling of women seeking FP services, and loss to follow-up were considered. The
calculated sample sizes were multiplied by a standard factor of 1.5 (design effect) and divided by 0.80 (20% loss
to follow up). This results in a total minimum sample size of 540 DMPA-SC users across both regions. The
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samples were divided equally between both regions with approximately 60 percent from the urban facilities
(Table 2).

TABLE 2. EXPECTED CLIENT SA MPLE SIZE, BY REGION
Ashanti

Volta

Health Facility 1
Health Facility 2

81
81

81
81

Health Facility or CHPS Compound 1
Health Facility or CHPS Compound 2

54
54
270

54
54
270

Urban/Peri-urban

Rural

Total

Thirty-two data collectors (16 per region) were recruited in October 2017 and trained in November 2017 to
conduct client interviews. In rural facilities where the expected client enrollment was 54, three data collectors
were recruited to conduct 18 interviews each. Likewise, five data collectors were recruited for each urban and
peri-urban facility where the expected client enrollment was 81. To equalize the number of interviews conducted
by each data collector, the enrollment was increased to 90 in the urban and peri-urban facilities.
In both regions, data collectors were trained over a 3-day period. The training included an overview of the study
and its goals; FP methods available and use trends in Ghana; the principles of research, including ethical conduct,
privacy, and confidentiality; the informed consent process and consent forms; the role of the data collector in
administering informed consent forms and ensuring confidentiality and privacy; review of the different study
instruments, interview questions, and their respective purposes; and data collection timelines and data
management.
Both trainings included a combination of PowerPoint presentations, quizzes, role-plays, and practice using the
tablets and troubleshooting data collection issues. The study instruments were developed in English and
translated orally into Ewe (the predominant language in the Volta region) and Twi (the predominant language
in the Ashanti region) during the trainings. In the event of disagreements, data collectors deliberated and came
to a consensus on terminology to use. Client interviews were conducted in the participant’s preferred language
(i.e., English, Ewe, or Twi), while the provider self-administered questionnaires were in English.

Providers
Providers completed self-administered paper-based questionnaires before and after the training in November
2017. The purpose of these questionnaires was to evaluate changes in knowledge related to FP counseling and
contraceptive methods in general, and particularly DMPA-SC counseling and administration, as a result of the
training received. The pre-training questionnaire gathered information on providers’ sociodemographic
characteristics (age, educational level, gender) as well as professional data (length of service provision, cadre,
average number of clients served per month). In addition, the questionnaire asked providers about FP counseling
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and provision experience as well as clinical practice. Providers completed the same questionnaire at pre-training
and post-training, although the latter included some additional questions about the training experience and selfreported preparedness to administer DMPA-SC and teach self-injection to clients.
Clients
Data collection with clients began in the first week of December 2017 in Ashanti Region and second week of
December 2017 in Volta Region. Three rounds of client interviews were conducted. Data collection about
clients’ first injection experiences ended in the last week of January 2018 in both regions. Data collection about
clients’ second and third injection experiences spanned March to April 2018 and June to July 2018, respectively.
The first interview was conducted immediately after the client first received DMPA-SC at the health facility, and
the second and third interviews were conducted at three-month intervals, at 3 months and 6 months, to
correspond with clients’ scheduled reinjection dates. The first interview was conducted in-person at the facility,
after the first injection. The majority of these interviews were conducted in a private space at the health facility,
although some clients preferred to be interviewed in another private space outside of the facility. Interviews at
3 months and 6 months were originally intended to be conducted over the phone after the scheduled reinjection
window for each client. However, some clients encountered connectivity issues, while others perceived that they
would face social harms for spending long periods of time on the phone, preferring instead that the interviews
be conducted face to face at the facility or at home, which the research team accommodated. Home self-injectors
identified a private space for the interview, usually in their homes.
The questionnaire about clients’ first injection experience included information on sociodemographic
characteristics, previous FP use, awareness of Sayana® Press, quality of care during the FP visit, Sayana® Press
counseling messages received, experiences with Sayana® Press injection training and administration, intention
to continue using Sayana® Press, home self-injection pack received (for those administering at home), and
reporting of serious adverse reactions. Additional questions in the 3-month and 6-month interviews focused on
the most recent injection experience, experience of side effects, and experiences with home self-injection for
those who chose to administer DMPA-SC at home, including ease of home self-injection, storage and disposal
of the device, and reinjection dates.
Clients who declined to participate in the study after the first injection, withdrew from the study by 3 months or
6 months, or discontinued using DMPA-SC by 3 months or 6 months were asked to participate in a separate
interview with questions about their reasons for declining, withdrawing, or discontinuing the method.
Health service statistics
DMPA-SC service delivery data were collected throughout the study using rsLog, a health management
information system (HMIS) tool developed by the GHS with technical assistance from Population Council.
Unlike the typical national HMIS used in the majority of West African countries into which aggregated data is
entered, rsLog allows for monitoring of individual health worker performance, by cadre; disaggregation of data
by facility, district, regional, and national levels; and generation of monthly electronic reports. Using rsLog, the
number of doses of DMPA-SC administered daily by cadre of health worker was captured. Data from rsLog
was collected for 10 months to help gauge continuation of DMPA-SC after the study period. Data from rsLog
was used for monitoring purposes and as part of the assessment of the feasibility of introducing DMPA-SC in
health facilities in Ghana. These data were not analyzed for this report.
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Provider responses from the pre- and post-training questionnaires were double entered manually into Census
and Survey Processing System (CSPro) by two different data analysts to reconcile any inconsistencies.
Interviews with clients were conducted using an electronic tablet pre-loaded with time-appropriate
questionnaires. Data collectors entered client responses into CSPro software installed on tablets. The data were
sent via a secure server to data supervisors who checked them for completeness and accuracy. Raw provider and
client data were accessible only to the research management team, namely the data supervisors, principal
investigator, program manager, research specialist, and the technical director. Only de-identified and aggregated
data were shared with stakeholders.

For both the provider and client data, descriptive statistics and bivariate analyses were conducted using Stata 15
software. Specifically, chi-square tests and t-tests were used to determine significant differences.

The research protocol, including the informed consent forms and data collection tools, was approved by the
Population Council Institutional Review Board in November 2016 and the GHS Ethical Review Committee in
April 2017.

Structured and written informed consent forms were administered in-person to providers before the trainings
began and to willing FP clients after taking their first DMPA-SC injection. All who agreed to participate in the
study were asked to sign the forms and were given a copy for their records. Clients who were not able to sign
their name attested that the consent form had been read and explained to them by a member of the research
staff by marking the space with an “x.” In subsequent rounds, clients provided verbal consent to data collectors
to conduct the interviews. The informed consent forms detailed the (a) study purpose, objectives, and duration;
(b) methodology; (c) interview procedures; (d) measures to protect their privacy, confidentiality, and anonymity
of information provided; (e) risks and benefits; (f) right to withdraw from the study or to refuse answering
questions at any point of the study; (g) compensation (clients were compensated with a bar of soap for their
time); (h) contact information of ethical review boards; and (i) who to contact for additional information or if
there was a problem. Master Trainers read the informed consent form to providers and explained its contents
and data collectors did the same with clients before seeking their written consent if they agreed to be part of the
study. All who declined to participate in the study were informed that they would be asked a few questions to
help understand their reasons, to which they were also given the choice to decline responding.

Each respondent was assigned a unique identification (ID) number prior to completing the first interview or
responding to the “Decline, Withdraw, or Discontinue” (DWD) interview. The unique ID was prefilled for
subsequent interviews. For providers, the unique ID was assigned when entering the data. As such, the
questionnaires with their names were kept in a locked cabinet at the Population Council office in Accra, Ghana
and will remain locked until 2022 as per Population Council research data and confidentiality procedures.
Informed consent forms were kept in a separate locked cabinet in the same office.
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Technical Advisory Group
The Population Council convened a Technical Advisory Group (TAG) in August 2016 to discuss and agree on
the self-injection study objectives. Comprising stakeholders from the public, private, and non-governmental
sectors (see Table 3 for list of participant organizations), the TAG remained active to provide guidance on study
regions, study design and methods, study intervention, product registration approach, and expected roles of
study partners. The diverse composition of the TAG was deliberate and based on the expected private sector
role in the event of a scale-up of DMPA-SC. The TAG held six face-to-face meetings between August 2016 and
November 2018 during which data collection updates were presented, findings discussed, and input and
feedback received. Outside of face-to-face meetings, the TAG remained engaged throughout the study period
via regular email updates.

Sayana® Press was approved as a contraceptive product by the Food and Drugs Authority (FDA) in November
2016, paving the way for discussions with the Regional Health Directorates of the Ashanti and Volta Regions.
In both regions, meetings were held in January 2017 with the Regional Health Director, Deputy Director for
Public Health (DDPH), and the Regional Public Health Nurse to discuss the study, intervention, and proposed
study sites. Upon agreement, the Regional Health Directors delegated their DDPH to further inform respective
District Directors and Facility In-charges.

Inception meetings were organized in the two regions: one in the Ashanti region in February 2017 and another
in the Volta region in March 2017. In both regions, meetings were attended by the GHS leadership at the
regional, district, and facility levels. The meetings were also attended by the leadership of the GHS Family Health
Division (national) and by representatives of USAID/Ghana’s Health, Population, and Nutrition Office. The
meetings included a presentation on the study rationale, objectives, intervention, and other proposed activities,
followed by discussions on topics such as storage, waste, disposal, stock availability, and pricing of DMPA-SC.

All In-Charges of the facilities communicated their willingness to be selected as a study site to the Regional
Health Directorate. In October 2017, the study team visited the eight study facilities to engage directly with the
In-Charges as well as the providers to discuss the study, introduction of DMPA-SC in Ghana using Sayana®
Press, a recap of the inception meeting, and the provider trainings. This was also an opportunity for providers
to ask questions and clarify that their training would be separate from their consent to participate in the research
study.

The study involved a three-step training cascade:

1. Training of Master Trainers
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The Family Health Division (FHD) of the GHS identified eight of its Regional Resource Trainers (four per
region) to be trained by a Master Trainer from PATH Uganda, a country where DMPA-SC and self-injection
feasibility and acceptability studies had been conducted. The 4-day training took place in mid-October 2017.
The training focused on DMPA-related topics outlined in Box 1 using PowerPoint slides derived from a
standardized training guide developed by PATH. At the request of the FHD, a one-page information sheet for
clients on adverse and severe adverse reactions as well as actions to take was developed and reviewed in the
training. This form was separate from the Adverse Reaction Reporting Form developed by the FDA for
pharmacovigilance and used by GHS. The training also included role-plays for providers to practice how to
administer DMPA-SC and train clients on self-injection.
Before the training, the Regional Resource Trainers completed a pre-training evaluation. They completed a posttraining evaluation on the last day of the training to ascertain gains in DMPA-SC knowledge from the training.
The PATH Master Trainer certified the Regional Resource Trainers as Ghana Master Trainers in DMPA-SC
and self-injection.

2. Training of health providers
The eight Ghana Master Trainers trained a total of
150 health providers (71 in Ashanti Region and 79 in
Volta Region) across the eight selected study
facilities. Each week in November 2017, 3-day
trainings were conducted simultaneously in each
region (except for 2-day trainings in two rural
facilities, due to small staff size). In each facility,
training was conducted among staff from various
FP-related departments (e.g., antenatal, reproductive
and child health, nutrition) and of different cadres
(i.e., community nurses, enrolled nurses, midwives,
and others) (Table 6).
The Ghana Master Trainers used the same PATH
resources and training guide to train the health
providers. The topics and lessons were delivered via
PowerPoint presentations, and hardcopies of the job
aids were made available. The tools used in the
training included:
1. Provider injection checklist: This checklist was used by
the Master Trainers to observe providers practicing
administering DMPA-SC injections on clients.

1.
2.

3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

General overview of family planning
Overview of DMPA
a. What is DMPA-SC?
b. What is Uniject™?
c. DMPA-IM and DMPA-SC: similarities and
differences
d. Mode of action and route of administration
Screening women for DMPA
Counseling women for DMPA
HIV risk and hormonal contraceptives including
DMPA
Safe storage and handling sharps
Provider-administered DMPA-SC injection
Counseling women on DMPA-SC self-injection
Training women to self-inject
Training clients to safely store DMPA-SC
Training clients to safely dispose of used Uniject™
devices
Training clients to calculate reinjection dates
Side effects management
Client follow up options

2. Observation checklist for Sayana® Press self-injection
practice: This observation checklist developed by PATH was used by the Master Trainers to observe providers
during their role play of training clients to practice DMPA-SC self-injection and by the providers to observe
clients during their actual practice of self-injection.
3. Reinjection calendar (2017-2018): This calendar spanning two years aided clients in remembering when to return
to the facility for reinjection or when to reinject at home. All home self-injection clients were given the calendar.
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4. Client self-injection instruction sheet: This one-page sheet (front and back) with pictorial instructions was designed
as a visual aid for clients to remember the steps required for safe self-injection. All home self-injection clients
were given this sheet.
5. Adverse Reaction Reporting Form: This form was developed by the FDA and is used by GHS as part of
pharmacovigilance. Providers were (re)trained to use this form to report adverse reactions to the GHS.
6. Adverse reaction information sheet for clients: This one-page sheet was developed for the purposes of the study to
help clients recognize the signs of severe adverse reactions and where to seek immediate medical attention.
7. DMPA-SC job aids for providers: These job aids developed by PATH were given to each provider to take back
to their facilities and use when providing DMPA-SC services.
Additionally, providers completed a self-administered questionnaire to determine their knowledge before the
training and a similar questionnaire after the training to gauge any changes in knowledge on FP in general and
DMPA-SC in particular. These questionnaires were developed for the purposes of the study.
In Volta region, providers were also trained on inputting data into rsLog, the health information system. No
trainings were needed in Ashanti region as providers in the study facilities were already using the rsLog system.

3. Training of family planning clients
Trained providers counseled FP clients at the facility on all
available contraceptive methods, including DMPA-SC and
on its two modes of administration (i.e., provideradministered or client self-administered). Among clients
who desired to use DMPA-SC, their eligibility to receive the
method was based on the World Health Organization’s
Medical Eligibility Criteria for Contraceptive Use (WHO
2015).

Step 1: Washes hands.
Step 2: Selects an appropriate injection site and
cleans it if needed.
Step 3: Opens the Sayana® Press pouch by tearing
from the notch.

Providers offered clients an option to be trained by the
provider to self-inject or to receive the injection by the
provider. If a client chose to self-inject, she was given the
opportunity to practice self-injection up to five times on a
condom filled with salt, to mimic the fat under skin, under
the supervision of the provider. The provider deemed the
client competent to self-inject when a client successfully
executed the five critical self-injection steps (out of 11 total
steps) (see Box 2, critical steps in bold), using the
observational checklist (tool #2 listed in training description
above) and his or her own clinical judgement. Providers also
trained self-injection clients on calculating future injection
dates, safe home storage, and safe disposal into a punctureproof container.

Step 4: Mixes the liquid by shaking the device
vigorously for about 30 seconds.

Clients who chose provider-administered injection and did
not practice self-injection or despite a self-injection practice,
clients who failed to be competent in self-injection were
informed about their follow-up visit, and the date for the

Step 11: Immediately places the used device in a
sharps disposal container without replacing the
needle cap.
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Step 5: Pushes the needle cap and port together to
activate the device.
Step 6: Removes the needle cap.
Step 7: Pinches the “skin” at the injection site to form
a “tent”.
Step 8: Inserts the needle completely so that the port
is in full contact with the skin.
Step 9: Presses the reservoir slowly to inject for about
5 to 7 seconds.
Step 10: Removes the device from the injection site
while still pinching the skin.

Bold indicates critical steps.

visit was indicated on their FP card. Clients who were trained to self-inject and deemed competent were given
up to two DMPA-SC doses for home self-injection, along with the 2017-2018 reinjection calendar with dates
for the next injections circled, the self-injection instruction sheet, and the puncture-proof disposable container
for disposing of the used devices. Self-injection clients were also asked to return the container with the used
devices to the facility at any point during the study for final disposal, but especially after the third injection when
they returned to receive additional doses.

The UNFPA procured 6,000 doses of DMPA-SC (Sayana® Press), which were sent to the Central Medical
Stores. Given that no requisition forms existed for the DMPA-SC, the commodities were transported to the
regional health directorates by the Evidence Project with approval from GHS-FHD and received by the
respective Regional Public Health Nurses.
The number of commodities per facility was determined by assuming a scenario in which all clients chose selfinjection. Calculations took into consideration the three doses needed for each client, regardless of mode of
administration, four doses needed for self-injection practice, and one dose to cover an additional three months
after the study. Each client was allocated a total of eight doses. An additional 30 percent of doses were added
for clients who selected DMPA-SC but declined participation in the study. A reserve of doses was stocked at
the regional medical stores for procurement during and after the study. Each rural facility received 562 doses of
DMPA-SC while each peri-urban and urban facility received 936 doses.

TABLE 3. LI ST OF ORGANIZATI ONS INVO LVED IN TECHNICAL AD VISORY GROUP
Organizations
United States Agency for International Development (USAID)
Ghana Health Service (GHS)
The Evidence Project, through Population Council
United Nations Population Fund (UNFPA)
Population Services International (PSI)
Strengthening Health Outcomes through the Private Sector
(SHOPS)
Pfizer, Inc.
Planned Parenthood Association of Ghana (PPAG)
Health Keepers Network (HKN)
DKT International

Sector represented
Donor
Public
INGO
Donor
INGO
INGO
Private
NGO
NGO
NGO – Social Enterprise

In both regions, Master Trainers conducted supportive supervision visits to each study facility three months
post-training (February 2018). At each facility, using the observation checklist for self-injection practice, Master
Trainers observed each provider simulating the steps for training clients to self-inject. Where necessary, the
Master Trainers aided providers to improve technique and reinforce knowledge. Additionally, Master Trainers
completed a supportive supervision form to assess the readiness of the facility and of providers to successfully
continue providing DMPA-SC services.
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Immediately following the data collectors’ training, a WhatsApp group was created for each region. The groups
included the respective data collectors, the research team, and the data management team. This platform was
used to exchange information from the research management team and for data collectors to initiate any
discussions related to tips or any challenges encountered during fieldwork. The platform also served as a tool
for continued supervision by the data management team.

Representatives from the TAG, specifically USAID/Ghana, GHS Family Health Division, and Population
Council, visited the Volta region in May 2018. Alongside two Master Trainers, the TAG representatives met
with the Regional Health Directorate followed by visits to Helekpe Health Centre and Council Hall Family
Health Unit. During these visits, they interacted with the providers and In-Charges. TAG members took the
opportunity to ask questions about providers’ experiences with DMPA-SC, training clients on self-injection, and
waste and disposal, as well as any implementation challenges encountered. Providers also took the opportunity
to ask questions about GHS’ plans for expansion and scale-up after the study ended.
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Across both regions, 568 clients who chose DMPA-SC agreed to participate in the study. Table 4 presents the
sociodemographic characteristics of clients enrolled in the study at the time of their first injection. More than
half of respondents were between 18 and 29 years old (60%), and the majority were married or in-union (73%).
Half had attained junior secondary school/junior high school (JSS/JHS) level (50%) and 22 percent had attained
senior secondary school/senior high school (SSS/SHS) level or higher. More clients were enrolled in urban areas
(60%), though by region, the distribution was almost equal. Enrollment by facility was a function of the estimated
sample size. Almost 60 percent of clients had previous experience using a modern or traditional FP method and
over three-quarters (76%) of respondents reported that their partner supported their use of FP. For most clients
(72%), the travel time to the facility was less than 30 minutes.
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TABLE 4. PERCENT D ISTRIBUTI ON OF STUDY PARTICIP ANTS BY
SOCIODEMOGRAPHIC CHA RACTERISTICS AT FIRST INJECTION (N=568)
Age group*
18-24
25-29
30-34
35-39
40-44
45+
Marital status
Never married
Ever married/in-union
Education
No education
Primary
JSS/JHS
SSS/SHS or higher
Region
Ashanti
Volta
Residence
Rural
Urban
Facility
Maternal & Child Health Hospital
Abuakwa Health Centre
Piase CHPS
Fumso Health Centre
Council Hall Family Health Unit
Helekpe Health Centre
Tsito Health Centre
Juapong Health Centre
Contraceptive experience
Previous FP user
New FP user
Partner supports FP use
No/don't know
Yes
Travel time to reach facility
Less than 30 minutes
30 minutes to 60 minutes
More than 60 minutes
Total
*Percentages may not add to 100 percent due to missing values
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N

Percent

185
156
107
62
33
24

32.6
27.5
18.8
10.9
5.8
4.2

155
413

27.3
72.7

55
107
282
124

9.7
18.8
49.7
21.8

278
290

48.9
51.1

226
342

39.8
60.2

90
79
54
55
84
55
62
89

15.9
13.9
9.5
9.7
14.8
9.7
10.9
15.7

334
234

58.8
41.2

137
431

24.1
75.9

410
130
28
568

72.2
22.9
4.9
100.0

Notably, 41 percent of respondents had never used any method of FP (Figure 3), while 59 percent had previously
used either a modern or traditional method (Table 4). Figure 3 shows the FP method most recently used by
clients before choosing DMPA-SC. Nearly half of respondents (48 percent) reported having used an injectable
most recently, and 6 percent reported having used an implant. The remaining 5 percent reported having used
oral contraceptive pills, withdrawal, male condoms, emergency contraception, abstinence, or the Standard Days
Method®.
FIGURE 3. MOST REC ENTLY U SED FAMILY PLANNING MET HOD AMONG DMPA-SC
CLIENTS (N=568)
Had not used a method previously

41.2

Injectable

47.9

Implant

6.2

Oral contraceptive pill

1.9

Withdrawal

0.9

IUD

0.7

Male condoms

0.5

Emergency contraceptive method

0.4

Abstinence

0.2

Standard Days Method®

0.2
0

25

50
Percentage

75

100

T H E EVI D EN CE PR OJ E CT | 2 1

During their FP counseling sessions, clients who selected DMPA-SC were offered an opportunity to be trained
in self-injection and, if deemed competent by the provider, could self-inject. Otherwise, the provider could inject
the DMPA-SC. Figure 4 shows the administration mode selected by clients at each injection among respondents
who were successfully interviewed at each follow-up interview. For the first injection, about one-third of clients
(35%) were successfully trained in and completed self-injection at the facility. At 3 months, 65 percent of clients
surveyed selected self-injection (21% on site at the facility and 44% at home), while 29 percent selected provideradministered injection and 7 percent discontinued using DMPA-SC. By the end of the study, at 6 months, most
clients (65 percent) selected self-injection (23% at the facility and 42% at home), 24 percent selected provideradministration, and 11 percent discontinued DMPA-SC.
FIGURE 4. CLI ENTS’ SELECTED MODE OF INJECTION AD MINISTRATION, BY
INTERVIEW
100

75

65.0

50

43.6

41.9

35.0
28.5

24.5 22.6

20.8

25

7.1

11.1

0
First injection (n=568)

Provider-administered

3 months (n=466)

On-site self-administered

Home self-injection

6 months (n=425)

Discontinued DMPA-SC

Figures 5-9 detail the distribution of clients’ selected administration mode of DMPA-SC at 6 months, by select
sociodemographic characteristics (additional information on mode of injection administration at each interview
by background characteristics is available in Appendix 2). Chi-squared tests of significance were conducted to
assess differences between provider-administered and self-injection. Those who self-injected at 3 months or 6
months, whether at home or at the facility, were grouped together as self-injectors for these chi-squared tests.
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Figure 5 presents clients’ mode of injection administration by age. There was a statistically significant difference
between age groups in choosing self-injection (p-value <0.05). At 6 months, about three-quarters of 18 to 24year-olds (78%), 25 to 29-year-olds (74%), and 30 to 34-year-olds (78%) were self-injection clients, compared to
65 percent of 35 to 39-year-olds and 51 percent of those 40 years and older. A greater proportion (49 percent)
of those 40 years and older chose provider-administration of DMPA-SC. Self-injectors comprised those who
self-injected at home and at the facility. Those 25 to 29 years old were most likely to have self-injected at home
at 6 months (56%), followed by 30 to 34 years old (50%) and 18 to 24 years old (45%). Those 35 to 39 years old
as well as 40 years and older were less likely to self-inject at home (36% of each age group). On-site self-injection
was most likely among those 18-24 (32 percent), followed by 35-39 (29%), and 30-34 (28%) years.
FIGURE 5. CLI ENTS’ MODE OF I NJECTION ADMINISTRAT ION AT 6 MONTH S, BY AGE
(N=378)
100

Percentage

75
56.3

50.0

45.5

50

25

27.9

26.0
17.7

35.9

35.6

35.6

32.1
22.3

48.7

28.9

22.1
15.4

0
18-24
(n=112)
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(n=96)
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Statistical difference in self-injection by age group: p-value ≤0.05

35-39
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40+
(n=39)

Home self-injection
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At 6 months, there was a significant difference between marital status groups (p-value <0.05) in self-injection of
DMPA-SC (Figure 6). Eighty one percent of never married clients and 69 percent of ever married/in-union
clients self-administered DMPA-SC, with 55 percent of never married clients and 44 percent of those ever
married/in-union being home self-injection clients. Similar proportions of ever-married/in-union women and
never married women self-injected on-site, at 25 percent and 26 percent, respectively. A greater percentage of
those who were ever married/in-union chose provider-administered injections (31%) compared to those who
were never married (20%).
FIGURE 6. CLI ENTS’ MODE OF I NJECTION ADMINISTRAT ION AT 6 MONTH S, BY
MARITAL STATUS (N=37 8)
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Statistical difference in self-injection by marital status: p-value ≤0.05
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Never married
(n=113)
Home self-injection

There was no statistically significant difference in choosing self-injection among educational groups at 6 months,
with 64 percent of those with no education, 79 percent of those with primary, 70 percent of those with JSS/JHS,
and 78 percent of those with SSS/SHS self-injecting at 6 months (Figure 7). However, there appears to be an
increase in specifically home self-injection by education level, as 35 percent of those with no education, 40
percent of clients with primary, 48 percent with JSS/JHS, and 56 percent of those with SSS/SHS chose to selfinject at home at 6 months. More than one-third of those with primary education chose to self-inject on-site, at
39 percent, followed by 29 percent of those with no education. Similar proportions of those with junior and
senior or higher levels of education self-injected on site, at 22 percent each.
FIGURE 7. CLI ENTS’ MODE OF I NJECTION ADMINISTRATION A T 6 MONTH S, BY
EDUCATION (N=378)
100

Percentage

75
55.7
47.6

50

35.5

38.6 40.0

35.5

30.7

29.0

21.7

21.4

25

22.7 21.6

0
No education
(n=31)

Primary
(n=70)

JSS/JHS
(n=189)

SSS/SHS or higher
(n=88)

Education
Provider-administered

On-site self-injection

Home self-injection

No statistical difference in self-injection by education
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Respondents who lived in rural locations were significantly more likely to self-inject at 6 months than those in
urban locations, with 87 percent of those living in rural locations choosing to self-inject compared to 64 percent
of those in urban locations (Figure 8). For home self-injection specifically, 80 percent of respondents living in
rural locations chose to self-inject at home, compared to 27 percent of those living in urban areas, whereas 37
percent of women in urban areas chose on-site self-injection compared to 7 percent of rural women.
FIGURE 8. CLI ENTS’ MODE OF I NJECTION ADMINISTRAT ION AT 6-MONTHS, BY
RESIDENCE (N=378)
100
79.9

Percentage

75

50
36.8

36.3

26.9
25

13.2
6.9
0
Urban
(n=234)
Provider-administered

Residence
On-site self-injection

Statistical difference in self-injection by residence: p-value ≤0.05
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Home self-injection

Figure 9 demonstrates that those who were first-time FP users were significantly more likely to self-inject, at 81
percent, than those who had used a modern or traditional method of FP prior to using DMPA-SC, at 65 percent.
A greater proportion (53%) of first-time FP users also self-injected at home compared to previous FP users
(43%), while similar proportions self-injected on-site (28% of first-time FP users compared to 23% of previous
FP users).
FIGURE 9. CLI ENTS’ MODE OF I NJECTION ADM INISTRATION AT 6 MONTH S, BY
HISTORY OF FAMILY PL ANNI NG USE (N=378)
100

Percentage

75

53.0
50

42.5
34.4
28.3

25

23.1

18.7

0
First-time FP users
(n=166)

Provider-administered

Previous FP use
On-site self-injection

All previous FP users
(n=212)

Home self-injection

Statistical difference in self-injection by history of FP use: p-value ≤0.05
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Figure 10 presents the proportion of clients who continued to use DMPA-SC through the end of the study, that
is, a total of 9 months of protection. At 3 months, 76 percent of clients continued using DMPA-SC, 6 percent
had discontinued using DMPA-SC, and 18 percent had withdrawn from the study or were lost to follow-up. By
6 months, 67 percent of clients were still using DMPA-SC, while 8 percent had discontinued3 using DMPA-SC,
and 25 percent had withdrawn from the study or were lost to follow-up.
FIGURE 10. CONTI NU ATION AND D ISCONTINUATION OF DMPA-SC AND STUDY
WITHDRAWAL/LOSS TO F OLLOW-UP, BY INTERVIEW (N=568)
100

100.0

76.2

Percentage

75

66.6

50

25.2

25

18.0
5.8

8.3

3 months (n=568)

6 months (n=568)

0
First injection (n=568)
Continued DMPA-SC

Discontinued DMPA-SC

Withdrew/lost to follow-up

Table 5 presents differences in continuation of DMPA-SC at 6 months by client characteristics. Continuation
of DMPA-SC includes provider-administered, on-site self-injection, and home self-injection clients.
Discontinuation includes those who stopped using DMPA-SC, those who were lost to follow-up, and those
that withdrew from the study. There were no significant differences in continuation of DMPA-SC by age,
education, urban/rural residence, and travel time to reach the facility. However, continuation was statistically
different by marital status, with those who were never-married (74%) being more likely to continue using than
those who were currently married (65%), and those who were formerly married being the least likely to
continue (59%). There were also statistically significant differences in continuation by region, with respondents
in Volta region being more likely to continue (75%) than those in Ashanti region (57%). Those who had
previous experience using FP were less likely to continue using DMPA-SC (64%) compared with new FP users
(71%) although, the relationship was not statistically significant (p-value <0.1).

3

Data were not collected on whether discontinuers of DMPA-SC switched to another FP method.

2 8 | R ES E AR C H R EP O RT

TABLE 5. CONTI NUATION OF DMPA-SC AT 6 MONTH S BY CLIENT BACKGROUN D
CHARACTERISTICS (N=5 68)
Discontinued (%)
Age group
18-24 (n=185)
33.0
25-29 (n=156)
37.2
30-34 (n=107)
32.7
35-39 (n=62)
24.2
40+ (n=57)
35.1
Marital status†
Never married (n=155)
26.5
Currently married/in-union (n=323)
34.7
Formerly married/in-union (n=90)
41.1
Education
No education (n=55)
43.6
Primary (n=107)
34.6
JSS/JHS (n=282)
33.0
SSS/SHS or higher (n=124)
29.0
Region†
Ashanti (n=278)
42.4
Volta (n=290)
24.8
Residence
Rural (n=226)
36.3
Urban (n=342)
31.6
Contraceptive experience
Previous FP user (n=334)
36.5
New FP user (n=234)
29.1
Travel time to reach facility
Less than 30 minutes (n=410)
32.2
30 minutes to 1 hour (n=130)
39.2
More than 1 hour (n=28)
25.0
Total (n=568)
33.5
†p-value <0.05 indicating significant differences

Continued (%)

p-value

67.0
62.8
67.3
75.8
64.9

0.481

0.050
73.5
65.3
58.9
0.291
56.4
65.4
67.0
71.0
<0.001†
57.6
75.2
0.245
63.7
68.6
0.063
63.5
70.9
0.208
67.8
60.8
75.0
66.5
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Clients who discontinued using DMPA-SC but were not lost to follow-up reported a variety of reasons for
discontinuing the method (Figure 11). Experiencing side effects was the most common reason, as reported by
44 percent of clients who discontinued using DMPA-SC. Approximately 23 percent reported inconvenience as
a reason for discontinuation, while 16 percent discontinued to switch to a different method of FP. Other reasons
for discontinuing included that the client was traveling, the possibility of experiencing adverse or serious effects,
the fear of getting pregnant, wanting to become pregnant, difficulty storing the devices, and an unsupervised
injection environment. Nine percent did not list a reason for discontinuing.
FIGURE 11. CLI ENTS’ REPORTED REASONS FO R DISCONTINUING DMPA-SC AT 3
MONTHS OR 6 MONTHS (N=80)
Experienced side effects

43.8

Inconvenience

22.5

Switched to a new method

16.3

Traveled

7.5

Possible adverse or serious effects

6.3

Mistrust in the product/fear of getting pregnant

3.8

Wants to become pregnant

3.8

Storage difficulty

1.3

Unsupervised environment

1.3

Other

8.8

No reason

8.8
0

3 0 | R ES E AR C H R EP O RT

25

50
Percentage

75

100

Clients who had selected self-injection and were deemed competent to self-inject were given up to two DMPASC doses to take home. Those who self-injected at home at 3 months (n=203) and at 6 months (n=178) were
asked about different aspects of acceptability of home self-injection (Figure 12). Clients reported high levels of
satisfaction (100% at 3 months and 98% at 6 months) and high levels of comfort with their home self-injection
experience (100% at 3 months and 6 months). Ninety-five percent at 3 months and 97 percent at 6 months
reported that they would recommend DMPA-SC home self-injection to a friend. Almost all intended to continue
home self-injection in the future (98% at 3 months and 97% at 6 months).
FIGURE 12. ASP ECTS OF ACCEPTA BILITY AMONG HOME SE LF-INJECTION CLIENTS
AT 3 MONTHS AND 6 MONTHS
100

99.5

97.8

99.5 100.0

94.6

96.6

97.5

97.2

Percentage

75

50

25

0
Satisfied with home self- Comfortable with home
injection experience
self-injection experience
3 months (n=203)

Would recommend
DMPA-SC home selfinjection to a friend

Intends to continue selfinjecting at home in
future

6 months (n=178)
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Home self-injection clients reported on the benefits of self-injecting at home (Figure 13). The benefit most often
cited was not having to travel to the facility (75% at 3 months and 71% at 6 months). Other benefits commonly
reported by home self-injection clients included not having to pay for travel to the facility (48% at both rounds),
injecting in the comfort of their own home (45% at 3 months and 53% at 6 months), injecting on their own time
(44% at 3 months and 45% at 6 months), and not having to wait at the facility (40% at 3 months and 47% at 6
months).

FIGURE 13. REPORTED BENEFITS OF HOME SELF -INJECTION AMONG CLIENTS WHO
SELF-INJECTED AT H OM E AT 3 MONTHS OR 6 MONTHS
Has experienced at least one benefit of home selfinjection

88.7
85.4
74.9
71.3

Did not have to travel to facility
Did not have to pay for travel to facility

48.3
48.3

Could inject in the comfort of own home

45.3
52.8
43.8
44.9

Could do it on own time

40.4
46.6

Did not have to wait at facility

39.4
41.6

Visual privacy for family planning use
23.6

Did not have to see provider
0

3 months (n=203)
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Self-injection clients were trained on how to properly store the DMPA-SC doses and dispose of the used
Uniject™ devices, and were asked at 3 months and 6 months how they stored and disposed of the devices
(Figure 14). Ninety-one percent of home self-injection clients reported correctly storing the doses in a cool, dry
area at room temperature, and this increased to 96 percent at 6 months. Nearly all home self-injection clients
reported correctly disposing of the used Uniject™ in a coverable and puncture-proof container (99% at 3
months and 98% at 6 months). At 3 months, 24 percent of home self-injection clients reported returning the
puncture-proof container to the health facility and this proportion rose to 37 percent at 6 months. Because
respondents would have had only two used devices to dispose of during the study period and a re-supply would
only have been necessary at 9 months, returning the container4 to the health facility was not necessary by 6
months.

FIGURE 14. CLI ENTS’ METHODS F OR STORAGE AND DISPO SAL OF THE DMPA-SC
UNIJECT™
100

90.6

98.5

95.5

98.3

Percentage

75

50
36.5
24.1

25

0
Correctly stored in cool, dry area
at room temperature

Correctly disposed in coverable
and puncture-proof container

3 months (n=203)

Returned container to health
facility during study period

6 months (n=178)

The container used in this study could hold up to 5 used Uniject™ devices comfortably (see Appendix 3 for example of
the puncture-proof containers).
4
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Figure 15 presents clients’ reported ease of storage and disposal of DMPA-SC. Almost all of home self-injection
clients found it easy to store the DMPA-SC doses (95% at 3 months and 94% at 6 months), and at each interview,
96 percent found it easy to dispose of the used device.
FIGURE 15. EASE OF STORAGE AN D DISPOSAL OF DMPA-SC
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93.8

96.1

96.1

Percentage
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50

25

0
Easy to store
3 months (n=203)
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6 months (n=178)

Clients who chose home self-injection were trained on how to calculate future reinjection dates and were given
a reinjection calendar to aid their calculation. Figure 16 illustrates clients’ reported reinjection time at 6 months,
among those who self-injected at home at both 3 months and 6 months. Reinjection time was calculated by
counting the days between the reported date of a client’s most recent injection at 3 months and the reported
date of a client’s most recent injection at 6 months. Those who reinjected within the 11-to-17-week reinjection
window were considered to have reinjected on-time (PATH 2018), while those who did so before 11 weeks had
elapsed were considered early and those who reinjected after more than 17 weeks were considered late. Eightyfive percent of self-injectors reported reinjecting on time, while 13 percent reported reinjecting early and 3
percent reported reinjecting late.
FIGURE 16. CLI ENTS’ REPORT OF REINJECTION TIME AT 6 MONTHS AMONG THOSE
WHO SELF-INJECTED AT HOME AT 3 MONTHS AND 6 MONTHS (N=159)
100
84.9

Percentage

75

50

25
12.6
2.5
0
On time (11-17 week reinjection
window)

Early (less than 11 weeks)

Late (more than 17 weeks)

T H E EVI D EN CE PR OJ E CT | 3 5

A total of 150 providers were trained across the two study regions. Table 6 presents their background
characteristics. The majority of trained providers were under 35 years of age (74%), female (91%) and had
completed nursing training college (85%). Although represented by different cadres, almost two-thirds of
providers were community health nurses (CHNs). Eighty-eight percent of providers had at least one year of
professional experience in their current role, while 81 percent had at least one year of experience providing FP
services. A slightly higher proportion of providers were trained in Volta region (53%) compared to Ashanti
region (47%). Most facilities had between 21 and 25 FP-related providers trained (a combination of on-site and
outreach providers); however, Piase CHPS and Tsito Health Centre, two facilities with smaller client volumes,
each had seven providers trained.

3 6 | R ES E AR C H R EP O RT

TABLE 6. PERCENT D ISTRIBUTI ON OF PROVIDERS BY S OCIODEMOGRAPHIC
CHARACTERISTICS (N=1 50)
Age group*
19-24
25-29
30-34
35-39
40-44
45+
Gender
Male
Female
Education completed
Senior secondary/High school
Nursing training college
University (undergraduate)
Post graduate degree
Other professional certificate
Professional cadre*
Enrolled Nurse
Community Health Nurse (CHN)
Community Health Officer (CHO)
Midwife
Other
How long have you been working in this professional capacity?*
Less than 1 year
1-4 years
5-9 years
10-19 years
20 or more years
How long have you been providing FP*
Less than 1 year
1-4 years
5-9 years
10 or more years
Region
Ashanti
Volta
Residence
Rural
Urban
Facility
Maternal & Child Health Hospital
Abuakwa Health Centre
Piase CHPS
Fumso Health Centre
Council Hall Family Health Unit
Helekpe Health Centre
Tsito Health Centre
Juapong Health Centre
Total

N

Percent

8
41
61
8
3
10

5.3
27.3
40.7
5.3
2.0
6.7

14
136

9.3
90.7

5
127
6
4
4

3.3
84.7
4.0
2.7
2.7

9
98
9
21
10

6.0
65.3
6.0
14.0
6.7

13
59
41
23
9

8.7
39.3
27.3
15.3
6.0

16
58
36
27

10.7
38.7
24.0
18.0

71
79

47.3
52.7

59
91

39.3
60.7

21
21
7
22
24
23
7
25
150

14.0
14.0
4.7
14.7
16.0
15.3
4.7
16.7
100.0

*Percentages may not add to 100 percent due to missing values

T H E EVI D EN CE PR OJ E CT | 3 7

Figure 17 shows changes in provider knowledge of DMPA-SC from the pre-training self-administered
questionnaire to the post-training self-administered questionnaire. Significant increases were observed across
four knowledge questions. Provider knowledge that: the Uniject™ is the type of injection system used for
DMPA-SC increased from 34 percent to 98 percent (p-value <0.001), DMPA-SC is administered subcutaneously
increased from 29 percent to 93 percent (p-value <0.001), DMPA-SC is administered every three months
increased from 52 percent to 99 percent (p-value <0.001), and DMPA-SC is stored at room temperature
increased from 55 percent to 100 percent (p-value <0.001).

FIGURE 17. CHANGES IN PROVIDE R KNOWLEDGE OF DMPA-SC FROM PRETRAINING TO POST -TRAINI NG (N=150)
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100

99.3

92.7

100.0
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50
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25
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How DMPA-SC is
administered subcutaneous†
Pre-training

† p-value <0.001
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temperature†

Providers were asked where on the body DMPA-SC can be administered. Figure 18 shows that when comparing
pre- and post-training responses, more providers correctly identified the location of DMPA-SC administration
after receiving the training. While significant increases in knowledge were observed for upper arm (27% to 57%),
abdomen (30% to 97%), and upper thigh (45% to 98%) as possible injection sites, only a little more than half of
respondents recalled the upper arm as one such site at post-training, likely because the upper arm was not
emphasized during the training due to it being a difficult location for clients to self-inject. Overall, all providers
knew of at least one location where DMPA-SC could be administered after receiving the training.
FIGURE 18. CHANGES IN PROVIDE R KNOWLEDGE OF WHERE DMPA-SC CAN BE
ADMINISTERED FROM PR E-TRAINING TO POST -TRAINING (N=150)
96.7

100
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100.0
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50
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25
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†p-value <0.001
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Almost all providers reported that they were very well prepared to offer DMPA-SC services after the training
(Figure 19). Ninety-four percent of providers felt very well prepared to counsel clients on DMPA-SC, 93 percent
felt very well prepared to administer DMPA-SC and to train clients to self-inject, and 97 percent felt very well
prepared to observe and supervise clients during self-injection.
FIGURE 19. PROVID ER-REPORTED PREPARED NESS TO OFFE R DMPA-SC SERVIC ES
AT POST-TRAINI NG (N= 150)*
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Not well prepared
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self-injection

Somewhat well prepared

*Percentages may not add to 100 percent due to missing values
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This study assessed the feasibility and acceptability of the subcutaneously administered injectable contraceptive
known as DMPA-SC, or by its brand name Sayana® Press. The study assessed feasibility and acceptability from
the perspective of: (1) service providers in Ghana who received training on DMPA-SC administration and on
how to train clients to self-inject and (2) Ghanaian FP clients who voluntarily selected the subcutaneous
injectable after counseling. At each injection time over a 6-month period (covering 3 injections), DMPA-SC
clients chose between provider-administered injection or self-injection on each of these occasions. Results of
the study have been used to inform the scale-up of DMPA-SC, including self-injection, in Ghana’s public and
private sectors.

Approximately two out of five DMPA-SC clients in this study (41%) had never used any method of FP, while
48 percent of clients had recently used intramuscular injectables (DMPA-IM). Many new users (70%) continued
to use the method through the study duration, suggesting that DMPA-SC is a feasible and acceptable option for
new users of FP. Adding DMPA-SC to the method mix in Ghana will provide an additional FP option and
increase the range of methods offered, which will increase choice for method selection. Reaching both new and
previous users of FP with this new method could lead to an increase in modern contraceptive use (Ross and
Stover 2013), helping Ghana to meet its FP2020 goals.

This study originally estimated that by 6 months, 25 percent of DMPA-SC users would choose to self-inject.
While just over one-third of DMPA-SC clients chose to self-inject the first time they used DMPA-SC (35%),
nearly two-thirds (65%) chose to self-inject at both 3 months and 6 months, suggesting that women may become
more comfortable with self-injection after receiving their first injection from the provider. Self-injection was
selected more often among 18 to 34-year-olds, never-married women, first-time FP users, and women living in
rural areas.
These data confirm that self-injection is acceptable to a variety of women and specifically has the potential to
reach vulnerable and marginalized populations with contraceptive needs. For example, women who live in rural
areas may live further away from facilities that offer FP and could benefit from an option that allows them to
self-inject in the home and return to the facility less often (if at all). Younger and never-married women may
value new discrete and private ways of using contraception through self-injection. Expanding the availability of
DMPA-SC to the private sector in addition to the public sector may be an opportunity to reach additional
women for whom pharmacies and medical sellers are the preferred source of FP due to locations, hours, and
privacy, among other conveniences.

This study followed women through three cycles of DMPA-SC injection. By 6 months, two out of three (67%)
women were still using DMPA-SC, a total of 9 months of protection. Continuation was more common in select
subgroups, such as never-married women, women from Volta region, and new FP users. Most women who
discontinued (n=80) did so due to method-related reasons, including the experience of side effects (44%), though
others found DMPA-SC inconvenient (23%) or switched to a different FP method (16%). The proportion of
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discontinuation due to side effects found in the present study is similar to that of DMPA-IM, where, according
to the latest Demographic and Health Survey in Ghana, 44 percent of episodes of DMPA-IM use were
discontinued due to side effects (GSS 2015).
These findings highlight DMPA-SC’s high acceptability and its potential to reduce known barriers to
continuation of contraceptive use, especially for clients that may be harder to reach, including never-married
women and new FP users. The findings also demonstrate the importance of supporting women who experience
side effects to manage their side effects or those or want to discontinue for other reasons to switch to a different
FP method as long as their desire to prevent pregnancy remains.

At 3 months, nearly two-thirds (65%) of DMPA-SC clients chose self-injection, including 21 percent that
returned to the facility to self-inject in the presence of a provider and 44 percent who self-injected at home.
Furthermore, clients who took DMPA-SC doses home reported high satisfaction (98% at 6 months) and comfort
(100% at 6 months) with home self-injection, and over 85 percent reported experiencing at least one benefit of
home self-injection, such as not having to travel to the facility, not having to wait at the facility, increased visual
privacy, and not having to be attended by the provider at the facility. These findings resonate with those of other
self-injection studies (e.g., Burke et al. 2014; Cover et al. 2017a) and highlight self-injection of DMPA-SC as a
self-care method that can increase women’s reproductive autonomy and decision making about timing, spacing,
and limiting of childbearing (Murray et al. 2017). In addition to being acceptable to women, responses from
interviews confirm that home self-injection is a feasible way to use DMPA-SC. For the majority of women who
chose this mode of administration at 6 months, they knew how to correctly store (96%) and dispose of (98%)
the used Uniject™ device, found it easy to store (94%) and dispose of (96 percent), and reinjected on time (i.e.,
11 to 17 weeks after last injection) (85%). However, 15 percent did not reinject on-time, with 13 percent injecting
early and 2 percent injecting late. This suggests that additional training on calculating and remembering
reinjection dates would be helpful for home self-injection clients. This may include text message reminders or
pocket calendars so that women can identify the reinjection period for the year based on the date of the first
injection.

Training service providers to administer DMPA-SC as well as to train clients to self-inject was feasible, likely
due in part to the fact that: (1) even the lowest cadre of GHS service providers, i.e., community health nurses,
are already trained to offer intramuscular contraceptive injectables as well as subcutaneous vaccinations and (2)
in-service/on-the-job training was conducted among all providers affiliated with FP at the facility. The training
that providers participated in focused on the features of DMPA-SC and client self-injection practice through
role plays, which were effective in significantly increasing provider knowledge of key DMPA-SC characteristics.
After the training, at least 93 percent of providers could name the type of injection device used, how DMPASC is administered, the frequency of DMPA-SC injections, and how to store DMPA-SC, compared to less than
60 percent that could name each before the training. One hundred percent could name at least one location on
the body where DMPA-SC could be administered after the training, compared to 61 percent before the training.
These findings suggest that by using a standardized training curriculum, FP providers in Ghana can be trained
in DMPA-SC and can train clients in DMPA-SC self-injection.
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The training was effective in equipping providers with the tools to offer DMPA-SC services, as almost all
providers reported feeling very well prepared to provide DMPA-SC services after the training. Providers
reported feeling very well prepared to counsel women on DMPA-SC (94%), administer DMPA-SC to clients
(93%), train clients on self-injection (93%), and observe and supervise clients who choose self-injection (97%).
The hands-on training and supportive environment—role playing, injection practice, and opportunity to ask
questions—may have increased the confidence of providers to provide DMPA-SC services.

Providers did not systematically complete the self-injection practice observation checklist, citing that the steps
to observe were easy to memorize. However, this limited study results on one of the indicators of client selfinjection competence. The national scale up implementation should consider whether the practice observation
checklist would be a viable indicator of client competence during trainings.
Another limitation of this study was the possible introduction of selectivity bias by excluding FP clients who
were not unable to provide a phone number as a contact or unwilling to be reached by phone. The necessity of
a phone contact was due not only to the longitudinal nature of the study, but also the high chance of clients in
our sample opting for home self-injection. National data show that 90 percent or more of Ghanaian households
own a mobile telephone (GSS et al. 2015; Laary 2016). Nevertheless, it is possible that the characteristics of FP
clients who could not provide a phone number as a contact or were unwilling to be reached by phone would be
different from FP who could and were willing.
A third limitation of this study is that it did not include FP clients below 18 years old who sought services at the
study sites. While gaining the perspectives of adolescents on the feasibility and acceptability of DMPA-SC and
self-injection is important, the TAG decided to exclude this subgroup for two main, related reasons: first, to
protect the privacy, anonymity, and confidentiality of the adolescents in the event that their FP use was unknown
to their parents or guardians; and second, the short enrollment period could not allow time for data collectors
to locate all parents or guardians and seek their consent prior to seeking assent from the adolescent.
This study has several strengths:
•
•
•

•
•

This study responded to a direct need for evidence generation and added to the body of evidence on
subcutaneous contraceptive injection in low-resource settings.
This study followed clients prospectively over 6 months, reducing their recall bias in reporting on
experiences using DMPA-SC.
This study was deliberately designed for clients to decide voluntarily at each injection their preferred
administration method, allowing those who chose a provider-administered injection at their first
injection to still have the option to self-inject at 3 and/or 6 months and vice versa. As the proportion
of clients choosing self-injection nearly doubled from 35 percent at the first injection to 65 percent at 3
months and remained constant at 6 months, this study design showed that more clients may be willing
to choose self-injection after experiencing the first injection with a provider.
By completing this study, Ghana became the first example in sub-Saharan Africa of introducing DMPASC and self-injection simultaneously, and successfully doing so.
A multi-sectoral TAG was created intentionally to include private sector representatives that would
provide input from the start and utilize research findings to inform strategy in the event of a national
scale-up.
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•

Results from the research study have been used to inform the national scale up of DMPA-SC and selfinjection in public and private facilities, for which implementation planning by GHS began in January
2019. Members of the TAG were called to participate in and contribute to the scale-up working group.

The findings of this study suggest that providers can effectively counsel their clients on DMPA-SC, be trained
to provide DMPA-SC, and train clients who voluntarily choose the self-injection mode of administration. The
study findings also demonstrate that clients benefitted from the option to self-inject and the personalized training
and supervision by the health provider. Training providers to offer DMPA-SC services and train clients to selfinject could expand access to FP for new users and continuation of FP among current or previous FP users.
Though home self-injection was feasible for most women, particular attention and support may be needed to
ensure that home self-injection clients are able to reinject on time, safely store and dispose of DMPA-SC, and
manage side effects, and that those who want to discontinue for method-related reasons are able to switch to a
different FP method.
As of 2017, GHS has over 21,000 enrolled nurses and over 15,000 community health nurses (GHS 2018),
representing a substantial pool of lower cadre health personnel—more likely to be stationed in rural and periurban areas and to conduct outreach/home visits. As shown by this study, these providers can readily be trained
on DMPA-SC and client self-injection. The findings of this study support the national scale-up of DMPA-SC,
and the following considerations are recommended to assist the GHS:
:
•
•

•

Develop an implementation strategy for staggered rollout across the nation in public and private health
facilities.
Utilize a cascade training approach similar to the study, whereby national and regional resource persons
are trained to become Master Trainers, who then train providers on-site. This will efficiently maximize
the number of providers who are trained across the country.
Engage pharmacies and over-the-counter medical sellers in commodity resupply, enabling them to sell
DMPA-SC to women who have received self-injection training at the facility and amplifying the role of
the private sector in increasing uptake of DMPA-SC in Ghana.
:

•
•

Develop national guidelines and standards governing home self-injection of DMPA-SC, to be included
in the next edition of the National Reproductive Health Service Policy and Standards.
Develop national guidelines and standards for disposal and waste management of used devices for
facilities and home self-injection clients.
:

•

Raise awareness by integrating DMPA-SC in relevant health promotion and social marketing activities
in the community and at health facilities.
:

•

Enforce the use of the standard Adverse Reaction Reporting Form in public and private facilities as well
as pharmacies and over-the counter medical seller shops as part of pharmacovigilance.
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•
•
•

•

Add DMPA-SC and its modalities as a method option on FP registries and daily logs to enable public
and private facilities to contribute to national monitoring and reporting of DMPA-SC use.
Include global DMPA-SC indicators in monitoring and evaluation tools to enable comparisons of trends
with other countries.
Develop an action plan for monitoring disposal and waste management for facilities and home selfinjection clients. While 95 percent of clients stored DMPA-SC correctly and 98 percent disposed of it
correctly, this study did not follow women for long enough to know if they would also return their
disposal container to the facility at the time of resupply.
Conduct regular assessments of client experiences with DMPA-SC, including reinjection, storage, and
disposal practices, as well as reasons for discontinuation of DMPA-SC, and a comparison of these
reasons to those for discontinuation of DMPA-IM. As self-injection is a new mode of administration
in Ghana, monitoring its use from the clients’ perspective will be critical in understanding successes and
challenges of home injection for learning across the region.
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APPENDIX 1. STUDY PARTNERS AND ROLES
Partner

Roles

GHS
USAID
UNFPA
Population Council via
Evidence Project

Provide access to family planning users at public health facilities
Stakeholder and study funder
Supply DMPA-SC commodities (expected 6,000 doses)
Lead research study; coordinate implementation, data analysis, and research
utilization
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APPENDIX 2. CLI ENT’ S MODE OF I NJECTION ADMINISTRAT ION AT ALL INTERVIEWS, BY SOCIODEMOGRAPHIC
CHARACTERISTICS
First injection
On-site
Providerselfadministered injection

3 months

6 months

Total
(n)

Provideradministered

On-site selfinjection

Home selfinjection

Total
(n)

Provideradministered

On-site selfinjection

Home selfinjection

Total
(n)

Age group
18-24
25-29
30-34
35-39
40+

63.2
61.5
67.3
66.1
73.7

36.8
38.5
32.7
33.9
26.3

185
156
107
62
57

28.4
29.4
30.1
34.0
39.5

26.2
12.8
23.7
27.7
25.6

45.4
57.8
46.2
38.3
34.9

141
109
93
47
43

22.3
26.0
22.1
35.6
48.7

32.1
17.7
27.9
28.9
15.4

45.5
56.3
50.0
35.6
35.9

112
96
86
45
39

Marital status
Never married
Ever married/in-union

62.6
65.9

37.4
34.1

155
413

25.4
32.8

23.8
21.9

50.8
45.3

122
311

19.5
30.9

25.7
25.3

54.9
43.8

113
265

Education
No education
Primary
JSS/JHS
SSS/SHS or higher

74.6
70.1
65.6
54.8

25.5
29.9
34.4
45.2

55
107
282
124

40.0
24.1
33.0
27.7

28.6
39.8
17.7
16.0

31.4
36.1
49.3
56.4

35
83
221
94

35.5
21.4
30.7
22.7

29.0
38.6
21.7
21.6

35.5
40.0
47.6
55.7

31
70
189
88

Region
Ashanti
Volta

73.7
56.6

26.3
43.5

278
290

50.6
17.9

14.1
27.8

35.3
54.4

170
263

47.5
12.8

15.6
32.6

36.9
54.6

0.00
160
218

Residence
Rural
Urban

47.8
76.3

52.2
23.7

226
342

15.1
41.7

4.5
35.0

80.5
23.2

179
254

13.2
36.3

6.9
36.8

79.9
26.9

144
234

Use of family planning
First-time FP users
All previous FP users
Total
Percent

60.7
68.0
369
65.0

39.3
32.0
199
35.0

234
334
568
100.0

24.1
36.0
133
30.7

24.6
20.7
97
22.4

51.3
43.4
203
46.9

191
242
433
100.0

18.7
34.4
104
27.5

28.3
23.1
96
25.4

53.0
42.5
178
47.1

166
212
378
100.0
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APPENDIX 3. VI SUALS OF DISPOSABLE PUNCTURE -PROOF CONTAINER, AND USED
AND UNUSED U NIJEC T T M DEVIC ES

Photo credit: PATH
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